AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06086457 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: Camrelizumab (200mg, d1, Q3W) was continued until disease progression, unacceptable toxicity, death, physician or patient decision to withdraw, non-compliance, or discontinuation for administrative reasons (up to 35 cycles).
Study NCT04524442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arginine/lysine
Description: 1000 milliliters (mL) administered at a constant rate of 250 mL per hour
Study NCT06345079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cessation of somatostatin analogues
Description: Patients randomised to cease SSA will receive their last SSA injection ≥28 days prior to their first cycle of PRRT and will remain off SSA for the duration of the study. If there is concern from the treating team that a patient may experience a carcinoid flare after PRRT, then short acting octreotide is allowed to be used to control any symptoms.
Study NCT06345079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuation of somatostatin analogues
Description: Patients randomised to continue SSA will receive a SSA injection ≥28 days prior to their first cycle of PRRT, during PRRT and will continue receiving SSA every 4 weeks after PRRT.
Study NCT03760575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg via IV infusion every 3 weeks for 2 cycles 3 pre-surgery, for 4 cycles post-surgery and then every 3 weeks during maintenance.
Study NCT03760575 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Indocyanine Green (ICG) Image-Guided Surgery
Description: Standard surgery with image guided resection.
Study NCT03760575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m2 every 3 weeks via IV infusion for 4 cycles post-surgery.
Study NCT03760575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2 every 3 weeks via IV infusion for 4 cycles post-surgery.
Study NCT05688852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTX958
Description: Dose A VTX958
Study NCT05688852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTX958
Description: Dose B VTX958
Study NCT05688852 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VTX958 Placebo
Description: Placebo
Study NCT06122701 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Thiamin p.o.
Description: A single oral dose of thiamin will be administered in four intervention arms (arm 1: 200 mg, arm 2: 50 mg, arm 3: 10 mg, arm 4: 5 mg) as a drinking solution with 240 ml of still water after an overnight fast.~A total of 15 blood samples will be taken at defined time points (baseline; 0.25; 0.5; 0.75; 1.0; 1.5; 2.0; 2.5; 3.0; 3.5; 4.0; 6.0; 8.0; 10.0; 24.0 h). At each time point, blood will be collected (4.9 ml for plasma and 2.7 ml for whole blood) to determine thiamin, TMP and TDP, and biomarkers of OCT1 transport activity. Urine will be collected during the first 10 hours after thiamin administration.
Study NCT06122701 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Thiamin i.v.
Description: A single i.v. dose of thiamin 5 mg with 240 ml of still water after an overnight fast.~A total of 15 blood samples will be taken at defined time points (baseline; 0.25; 0.5; 0.75; 1.0; 1.5; 2.0; 2.5; 3.0; 3.5; 4.0; 6.0; 8.0; 10.0; 24.0 h). At each time point, blood will be collected (4.9 ml for plasma and 2.7 ml for whole blood) to determine thiamin, TMP and TDP, and biomarkers of OCT1 transport activity. Urine will be collected during the first 10 hours after thiamin administration.
Study NCT05803421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orforglipron
Description: Administered orally once daily
Study NCT05803421 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Administered SC once daily
Study NCT03896750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PA-824
Description: PA-824, a nitroimidazooxazine, used in prior studies of pretomanid is a novel TB treatment that is being investigated for use with other TB drugs to shorten and/or simplify regimens to treat either drug susceptible or resistant disease. After fasting for a minimum of 8 hours, subjects will receive one dose of 200 mg of pretomanid orally under direct supervision with 240 mL of water and a mouth check will be done.
Study NCT03896750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: PA-824, a nitroimidazooxazine, used in prior studies of pretomanid is a novel TB treatment that is being investigated for use with other TB drugs to shorten and/or simplify regimens to treat either drug susceptible or resistant disease. After fasting for a minimum of 8 hours, subjects will receive one dose of 200 mg of pretomanid orally under direct supervision with 240 mL of water and a mouth check will be done.
Study NCT06058702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Delta-9-THC
Description: Active Delta-9-THC (0.036 mg/kg) administered intravenously over 20 minutes.
Study NCT06058702 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Delta-9-THC
Description: Active Delta-9-THC (0.036 mg/kg) administered intravenously over 20 minutes.
Study NCT06058702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Control: Small amount of sterile 190 proof USP ethanol (1-2 mLs), with no THC, administered intravenously over 20 minutes.
Study NCT06058702 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control: Small amount of sterile 190 proof USP ethanol (1-2 mLs), with no THC, administered intravenously over 20 minutes.
Study NCT05573568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N,N-Dimethyltryptamine
Description: DMT will be administered using a vaporizer device in a single ascending fixed-order dosing regimen
Study NCT06167772 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BCAA
Description: branched-chain amino acid (bcaa) (ratio valine:leucine:isoleucine = 1.2:2:1) 40 g/day (leucine 19 g/day) form: powdered bcaa sealed in 8 g sachet package or bcaa parenteral 250 mL per bag.~frequency: 1 sachet bcaa dissolved in oral nutrition supplement (standard nutrition) 5 times per day, or bcaa parenteral, or combination of bcaa enteral \& parenteral.~duration: 10 days
Study NCT06167772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard nutrition
Description: Target energy of 20 kcal/kg BW/day Target protein ratio protein:non-protein calorie 1:70
Study NCT06167772 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard nutrition
Description: Target energy of 20 kcal/kg BW/day Target protein ratio protein:non-protein calorie 1:70
Study NCT06167772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard physiotherapy
Description: A symmetric biphasic rectangular pulse was employed, with a frequency of 100 Hz, pulse width of 500 µs, Ton 5 s, Toff 25 s, ramp up of 1 s and ramp down of 1 s.
Study NCT06167772 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard physiotherapy
Description: A symmetric biphasic rectangular pulse was employed, with a frequency of 100 Hz, pulse width of 500 µs, Ton 5 s, Toff 25 s, ramp up of 1 s and ramp down of 1 s.
Study NCT05784103 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Clarifi Modulum
Description: During consenting period, the Modulim equipment will be calibrated and setup ready for scanning. Subject's volar aspect of the thumb along with the palm surface will be ready to target the optical camera head. Actual scanning takes less than 60 seconds. The images will be processed offline. During processing 3-5 different regions of interest will be taken to measure the oxygen parameters such as tissue oxygen saturation, oxy-hemoglobin, deoxy-hemoglobin, superficial hemoglobin, and sub-surface hemoglobin.
Study NCT05784103 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Perimed PeriFlux 5000
Description: Transcutaneous oxygen monitoring (TCOM or TcpO2) is a noninvasive, clinically-approved method to obtain skin oxygen levels. The method is quantitative, and measures oxygen delivery to the skin from underlying tissue. Before positioning the electrode, an adhesive fixation ring will be placed on the dry skin on the volar aspect of the thumb and an electrolyte as a contact liquid will be filled half and the probe is aligned into it by rotating clock-wise to fasten it. Recording will be started and waited for the oxygen level to stabilize and a fixed value will be recorded. The probe will be heated to about 45oC. Although this device has other options, only the measurement of O2 will be performed using this device.
Study NCT05784103 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Apple Watch Oxygen Sensor
Description: The apple watch is equipped with green, red, and infrared LEDs that shine light onto the blood vessels in the wrist, with photodiodes measuring the amount of light reflected back. Apple's algorithms use this information to calculate the color of the blood, which is an indication of how much oxygen is in the blood. Bright red blood is well oxygenated, while darker blood has less oxygen. This can measure blood oxygen levels between 70 and 100 percent. Most healthy people have blood oxygen levels that range from 95 to 100 percent. The apple watch sensor will be positioned on the user's preferred wrist.
Study NCT05784103 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Innovo iP 900AP
Description: The pulse oximeter enables transcutaneous monitoring of the oxygen saturation of hemoglobin in arterial blood. In this study, volar aspect of thumb and index finder of the subject will be used to measure blood oxygen saturation.
Study NCT06234072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Astragalus + Gemcitabine
Description: Participants will receive Astragalus combined with Gemcitabine. Astragalus, a traditional Chinese medicine, exhibits promising potential in cancer treatment. Studies suggest its role in regulating immune responses, suppressing tumors, and improving overall treatment outcomes in cancer patients. Astragalus combined with chemotherapeutic drug such as Gemcitabine is a popular complementary and alternative therapy used for cancer patients because it can increase therapeutic effects and decrease side effects. This synergistic approach holds potential for more effective and targeted therapeutic outcomes in pancreatic cancer patients.
Study NCT06234072 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine alone
Description: Gemcitabine is a potent chemotherapy drug widely employed in treating various cancers, including pancreatic cancer. As a nucleoside analog, it disrupts DNA synthesis, impeding cancer cell proliferation. Gemcitabine is administered intravenously and has shown efficacy in alleviating symptoms, improving survival rates, and enhancing the quality of life for patients undergoing cancer treatment.
Study NCT06276049 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: custom GPT supported self-directed learning
Description: The intervention in our study involved a LearnGuide utilization guide course along with a 12-week integrated training program that incorporated LearnGuide. In the first two-hour session, instructional staff introduced LearnGuide through a hands-on demonstration, teaching students how to use ChatGPT effectively by crafting high-quality prompts. The team emphasized LearnGuide's role as an AI facilitator in self-directed learning (SDL). Following the introduction, students were assigned various tasks including online learning, literature reviews, case analyses, and Problem-Based Learning (PBL) activities. Over the 12-week SDL phase with LearnGuide, students were required to complete at least one of these tasks weekly. This setup allowed students to consult mentors for any LearnGuide-related questions, enhancing their learning experience.
Study NCT06423443 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Cognitive Behavioral Therapy
Description: digital cognitive behavioral therapy app
Study NCT06423443 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: traditional on-line health education app
Study NCT06423443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAU
Description: treatment as usual
Study NCT06423443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: treatment as usual
Study NCT05716386 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Low salt diet
Description: Low salt diet less than 2 gram per day
Study NCT05716386 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low salt diet
Description: Low salt diet less than 2 gram per day
Study NCT05204836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid Injection
Description: 5 mg / 100 mL intravenous infusion
Study NCT05204836 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mL intravenous infusion
Study NCT05187546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]-PI2620
Description: \[18F\]PI-2620 is a radioactive diagnostic agent being developed for the indication of PET imaging of the brain to detect tau pathology in adult patients who are being evaluated for neurodegenerative decline. All patients will receive two administrations of \[18F\]PI-2620 at a radioactive dose of 185 megabecquerel (MBq).
Study NCT05194605 — intervention group
Intervention type: OTHER
Intervention: Prediction model
Description: We develop and validate clinical models to predict treatment responses and survival outcomes in patients with biopsy-proven with osteosarcoma.
Study NCT05288855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voclosporin
Description: calcineurin inhibitor
Study NCT05288855 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: matching placebo capsule
Study NCT05768893 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Long-Pulsed Nd:YAG Laser 1064nm & Er:YAG Laser 2940nm
Description: Warts with this intervention treated firstly with the Er:YAG laser, followed by the Nd:YAG laser in the same session.
Study NCT05768893 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Er:YAG Laser 2940nm
Description: Warts with this intervention treated only with the Er:YAG laser.
Study NCT05722977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib + envafolimab
Description: Surufatinib: oral, fix dose 250mg, once a day; Envafolimab: subcutaneous injection, fix dose 300mg, once every three weeks
Study NCT06396988 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novamin application
Description: Teeth from this group will be treated with the application of Sensodyne Repair\&Protect Toothpaste for 28 days after each visit (1 application per day for 2 minutes).
Study NCT06396988 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Parodontax application
Description: Teeth from this group will be treated with the application of Parodontax Complete Protection Toothpaste for 28 days after each visit (1 application per day for 2 minutes).
Study NCT04835688 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transmyringeal ventilation tube insertion
Description: In both groups, the tympanic membrane will be anesthetized by local application of topical prilocaine (EMLA) or phenol or by infiltration anaesthesia of the outer ear canal. The choice of method is left to the discretion of the surgeon.~For the experimental group, insertion of a ventilation tube will be performed. An incision is performed, usually in the lower, anterior quadrant of the tympanic membrane and the transmyringeal tube is inserted.
Study NCT04835688 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham-treatment
Description: For the control group, the ENT-specialist will touch the tympanic membrane with an alligator ear forceps to simulate getting a paracentesis. In the same procedure, without having made a paracentesis, a ventilation tube is placed on the tympanic membrane and removed again afterwards. The reason for the above-mentioned is to simulate getting a paracentesis and insertion of a ventilation tube.
Study NCT05369793 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpha lipoic acid
Description: Administration of alpha-lipoic acid 600mg plus vildagliptin/metformin combination (50/1000mg) orally once daily for 3 months.
Study NCT05369793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast
Description: Administration of 500 mcg plus vildagliptin/metformin combination(50/1000mg) orally once daily for 3 months.
Study NCT04745390 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Patients will be randomized between standard of care palliative irradiation of 2000cGy in 5 fractions (Arm 1) versus radiobiologically guided dose selection also in 5 fractions (Arm 2). For all patients randomized, radiation is to be delivered in 5 fractions delivered over 5 to 15 days.
Study NCT04745390 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Description: Patients will be randomized between standard of care palliative irradiation of 2000cGy in 5 fractions (Arm 1) versus radiobiologically guided dose selection also in 5 fractions (Arm 2). For all patients randomized, radiation is to be delivered in 5 fractions delivered over 5 to 15 days.
Study NCT05538429 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: erector spinal plane combined with serratus anterior plane block
Description: The experimental group received ultrasound-guided erector spinal block combined with serratus anterior plane block, and erector spinal block was performed at the T5 and T7 levels with 10ml 0.4% ropivacaine for each level, and 20ml 0.4% ropivacaine for serratus anterior plane block. The control group received ultrasound-guided thoracic paravertebral block at T5 and T7 levels, respectively, with 20ml 0.4% ropivacaine at each level.
Study NCT05538429 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erector spinal plane combined with serratus anterior plane block
Description: The experimental group received ultrasound-guided erector spinal block combined with serratus anterior plane block, and erector spinal block was performed at the T5 and T7 levels with 10ml 0.4% ropivacaine for each level, and 20ml 0.4% ropivacaine for serratus anterior plane block. The control group received ultrasound-guided thoracic paravertebral block at T5 and T7 levels, respectively, with 20ml 0.4% ropivacaine at each level.
Study NCT05024890 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Splash WASH in Schools programme (Project WISE)
Description: The Project WISE intervention includes:~WASH infrastructure~* Water storage tanks and water filtration systems~* Durable plastic drinking water and handwashing stations~* New/rehabilitated toilet facilities (gender-segregated, wheelchair-accessible, well-lit, ventilated, durable door and lock)~Behaviour change promotion~* Training of focal teachers to organise student 'hygiene club'~* Annual soap drive and soap restocking~* Behavioural 'nudges' (posters and mirrors at handwashing stations, colourful vests for hygiene clubs)~MHM services~* Toilets have water tap, bucket and waste bin~* Emergency menstrual hygiene products available at school~* Training of focal teachers to organise student 'gender club'~* Education on puberty and menstruation for all pupils above 10 and parent resource guide
Study NCT06009198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron folate tablets
Description: Iron folate tablets will be administered to the underweight school going adolescents girls and boys to see the affect on BMI and micronutrients
Study NCT05241288 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Albuterol eMDPI DS
Description: Albuterol sulfate electronic multidose dry powder inhaler (Albuterol eMDPI) Digital System (DS) with 3 component devices:~Device 1: Albuterol eMDPI Device 2: Albuterol eMDPI Patient-facing smart device application (App) Device 3: Digital Health Platform (DHP, Cloud solution)
Study NCT04912661 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Ferinject
Description: intravenous iron carboxymaltose
Study NCT04992299 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Intervention
Description: 6-week mindfulness-based intervention of 6 weekly 1 hour group sessions
Study NCT04992299 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behavioral Therapy
Description: 6-week cognitive-behavioral therapy intervention of 6 weekly 1 hour group sessions
Study NCT04992299 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health Education
Description: 6-week health education didactic program of 6 weekly 1 hour group sessions
Study NCT04831593 — intervention group
Intervention type: OTHER
Intervention: Group El
Description: Gastric ultrasound is a point-of-care diagnostic tool to examine stomach contents and determine pulmonary aspiration risk at the bedside. Qualitative gastric sonography can determine the nature of gastric content ( empty, clear fluid or thick fluid/solid ) and quantitative gastric ultrasound can estimate the volume of gastric fluid.
Study NCT04831593 — intervention group
Intervention type: OTHER
Intervention: Group Em
Description: Gastric ultrasound is a point-of-care diagnostic tool to examine stomach contents and determine pulmonary aspiration risk at the bedside. Qualitative gastric sonography can determine the nature of gastric content ( empty, clear fluid or thick fluid/solid ) and quantitative gastric ultrasound can estimate the volume of gastric fluid.
Study NCT05305976 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: The 8 week exercise program with telerehabilitation
Study NCT05310760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vit C
Description: Oral vitamin C (100 mg three times daily for one week then 100 mg once daily for 1-3 months)